Role of immunosuppression in post-endoscopic retrograde cholangiopancreatography pancreatitis after liver transplantation: A retrospective analysis

Liver Transplantation

Volumn 19, Issue 12, 2013, Pages 1354-1360

  Law, Ryan ^a   Leal, Carlos ^b,c   Dayyeh, Barham Abu ^a   Leise, Michael D ^a   Balderramo, Domingo ^b,c   Baron, Todd H ^a   Cardenas, Andres ^b,c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEPREDNISONE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ACUTE PANCREATITIS; ARTICLE; CANNULATION; CORTICOSTEROID THERAPY; DATA BASE; DRUG DOSE REDUCTION; ELECTRONIC MEDICAL RECORD; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; SPHINCTEROTOMY; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ADULT; AGED; CHI-SQUARE DISTRIBUTION; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; FEMALE; HOSPITALS, HIGH-VOLUME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MINNESOTA; MULTIVARIATE ANALYSIS; ODDS RATIO; PANCREATITIS; PREDNISONE; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN; TIME FACTORS;

EID: 84889040087     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23758     Document Type: Article

References (45)

1. Balderramo D, Bordas JM, Sendino O, Abraldes JG, Navasa M, Llach J, Cardenas A,. Complications after ERCP in liver transplant recipients. Gastrointest Endosc 2011; 74: 285-294.
2. Colonna JO II, Shaked A, Gomes AS, Colquhoun SD, Jurim O, McDiarmid SV, et al. Biliary strictures complicating liver transplantation. Incidence, pathogenesis, management, and outcome. Ann Surg 1992; 216: 344-350.
3. Jeffrey GP, Brind AM, Ormonde DG, Frazer CK, Ferguson J, Bell R, et al. Management of biliary tract complications following liver transplantation. Aust N Z J Surg 1999; 69: 717-722.
4. Pfau PR, Kochman ML, Lewis JD, Long WB, Lucey MR, Olthoff K, et al. Endoscopic management of postoperative biliary complications in orthotopic liver transplantation. Gastrointest Endosc 2000; 52: 55-63.
5. Thuluvath PJ, Pfau PR, Kimmey MB, Ginsberg GG,. Biliary complications after liver transplantation: the role of endoscopy. Endoscopy 2005; 37: 857-863.
6. Seehofer D, Eurich D, Veltzke-Schlieker W, Neuhaus P,. Biliary complications after liver transplantation: old problems and new challenges. Am J Transplant 2013; 13: 253-265.
7. Ayoub WS, Esquivel CO, Martin P,. Biliary complications following liver transplantation. Dig Dis Sci 2010; 55: 1540-1546.
8. de la Mora-Levy JG, Baron TH,. Endoscopic management of the liver transplant patient. Liver Transpl 2005; 11: 1007-1021.
9. Rao AS, Baron TH,. Pancreatic stent placement for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: do we need further evidence? No, the defense rests. Endoscopy 2010; 42: 870-871.
10. Freeman ML, Guda NM,. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004; 59: 845-864.
11. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335: 909-918.
12. Andriulli A, Loperfido S, Napolitano G, Niro G, Valvano MR, Spirito F, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007; 102: 1781-1788.
13. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37: 383-393.
14. Sanna C, Giordanino C, Giono I, Barletti C, Ferrari A, Recchia S, et al. Safety and efficacy of endoscopic retrograde cholangiopancreatography in patients with post-liver transplant biliary complications: results of a cohort study with long-term follow-up. Gut Liver 2011; 5: 328-334.
15. Sanna C, Saracco GM, Reggio D, Moro F, Ricchiuti A, Strignano P, et al. Endoscopic retrograde cholangiopancreatography in patients with biliary complications after orthotopic liver transplantation: outcomes and complications. Transplant Proc 2009; 41: 1319-1321.
16. Akbar A, Abu Dayyeh BK, Baron TH, Wang Z, Altayar O, Murad MH,. Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 778-783.
17. Ding X, Chen M, Huang S, Zhang S, Zou X,. Nonsteroidal anti-inflammatory drugs for prevention of post-ERCP pancreatitis: a meta-analysis. Gastrointest Endosc 2012; 76: 1152-1159.
18. Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, et al.; for U.S. Cooperative for Outcomes Research in Endoscopy (USCORE). A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012; 366: 1414-1422.
19. Otsuka T, Kawazoe S, Nakashita S, Kamachi S, Oeda S, Sumida C, et al. Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. J Gastroenterol 2012; 47: 912-917.
20. Gross V, Leser HG, Heinisch A, Schölmerich J,. Inflammatory mediators and cytokines-new aspects of the pathophysiology and assessment of severity of acute pancreatitis? Hepatogastroenterology 1993; 40: 522-530.
21. Mäkelä A, Kuusi T, Nuutinen P, Schröder T,. Phospholipase A2 activity in body fluids and pancreatic tissue in patients with acute necrotising pancreatitis. Eur J Surg 1999; 165: 35-42.
22. Barzilai A, Ryback BJ, Medina JA, Toth L, Dreiling DA,. The morphological changes of the pancreas in hypovolemic shock and the effect of pretreatment with steroids. Int J Pancreatol 1987; 2: 23-32.
23. Friess H, Shrikhande S, Riesle E, Kashiwagi M, Baczako K, Zimmermann A, et al. Phospholipase A2 isoforms in acute pancreatitis. Ann Surg 2001; 233: 204-212.
24. Zhang XP, Chen L, Hu QF, Tian H, Xu RJ, Wang ZW, et al. Effects of large dose of dexamethasone on inflammatory mediators and pancreatic cell apoptosis of rats with severe acute pancreatitis. World J Gastroenterol 2007; 13: 5506-5511.
25. Budzyńska A, Marek T, Nowak A, Kaczor R, Nowakowska-Dulawa E,. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 2001; 33: 766-772.
26. De Palma GD, Catanzano C,. Use of corticosteroids in the prevention of post-ERCP pancreatitis: results of a controlled prospective study. Am J Gastroenterol 1999; 94: 982-985.
27. Manolakopoulos S, Avgerinos A, Vlachogiannakos J, Armonis A, Viazis N, Papadimitriou N, et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastrointest Endosc 2002; 55: 470-475.
28. Sherman S, Blaut U, Watkins JL, Barnett J, Freeman M, Geenen J, et al. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. Gastrointest Endosc 2003; 58: 23-29.
29. Zheng M, Bai J, Yuan B, Lin F, You J, Lu M, et al. Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis. BMC Gastroenterol 2008; 8: 6.
30. Bai Y, Gao J, Shi X, Zou D, Li Z,. Prophylactic corticosteroids do not prevent post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. Pancreatology 2008; 8: 504-509.
31. Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446-454.
32. Cennamo V, Fuccio L, Zagari RM, Eusebi LH, Ceroni L, Laterza L, et al. Can early precut implementation reduce endoscopic retrograde cholangiopancreatography-related complication risk? Meta-analysis of randomized controlled trials. Endoscopy 2010; 42: 381-388.
33. Masci E, Mariani A, Curioni S, Testoni PA,. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy 2003; 35: 830-834.
34. Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54: 425-434.
35. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48: 1-10.
36. Kwanngern K, Tiyapattanaputi P, Wanitpukdeedecha M, Navicharern P,. Can a single dose corticosteroid reduce the incidence of post-ERCP pancreatitis? A randomized, prospective control study. J Med Assoc Thai 2005; 88 (suppl 4): S42-S45.
37. Weiner GR, Geenen JE, Hogan WJ, Catalano MF,. Use of corticosteroids in the prevention of post-ERCP pancreatitis. Gastrointest Endosc 1995; 42: 579-583.
38. Steinberg W, Tenner S,. Acute pancreatitis. N Engl J Med 1994; 330: 1198-1210.
39. Lasser EC, Lang JH, Lyon SG, Hamblin AE, Howard M,. Glucocorticoid- induced elevations of C1-esterase inhibitor: a mechanism for protection against lethal dose range contrast challenge in rabbits. Invest Radiol 1981; 16: 20-23.
40. Dumonceau JM, Andriulli A, Deviere J, Mariani A, Rigaux J, Baron TH, Testoni PA,; for European Society of Gastrointestinal Endoscopy. European Society of Gastrointestinal Endoscopy (ESGE) guideline: prophylaxis of post-ERCP pancreatitis. Endoscopy 2010; 42: 503-515.
41. Choudhary A, Bechtold ML, Arif M, Szary NM, Puli SR, Othman MO, et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc 2011; 73: 275-282.
42. Andriulli A, Forlano R, Napolitano G, Conoscitore P, Caruso N, Pilotto A, et al. Pancreatic duct stents in the prophylaxis of pancreatic damage after endoscopic retrograde cholangiopancreatography: a systematic analysis of benefits and associated risks. Digestion 2007; 75: 156-163.
43. Mazaki T, Masuda H, Takayama T,. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: a systematic review and meta-analysis. Endoscopy 2010; 42: 842-853.
44. Singh P, Das A, Isenberg G, Wong RC, Sivak MV Jr, Agrawal D, Chak A,. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 2004; 60: 544-550.
45. Elmunzer BJ, Higgins PD, Saini SD, Scheiman JM, Parker RA, Chak A, et al.; for United States Cooperative for Outcomes Research in Endoscopy. Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data. Am J Gastroenterol 2013; 108: 410-415.